Allen Institute for Artificial Intelligence logo

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 months ago

Possible Interaction: Bumetanide and Gamma-Aminobutyric Acid

Research Papers that Mention the Interaction

Bumetanide , a selective NKCC1 chloride importer antagonist, may attenuate depolarizing GABA action , and in that way reduce disease burden.
Molecular Autism  •  2020  |  View Paper
Bumetanide has been reported to alter synaptic excitation–inhibition (E-I) balance by potentiating the action of γ-aminobutyric acid (GABA), thereby attenuating the severity of autism spectrum disorder (ASD) in animal models.
Translational Psychiatry  •  2020  |  View Paper
Bumetanide , a selective NKCC1 inhibitor, works as a potent agent for restoring the inhibitory function of GABA.
Psychiatry and clinical neurosciences  •  2017  |  View Paper
Bumetanide can decrease neuronal chloride concentrations and may thereby reinstate γ-aminobutyric acid (GABA)-ergic inhibition in patients with neurodevelopmental disorders.
Pediatrics  •  2015  |  View Paper
Blocking early GABA depolarization with bumetanide results in permanent alterations in cortical circuits and sensorimotor gating deficits [published online ahead of print July 19, 2010].
Journal of child neurology  •  2011  |  View Paper
Bumetanide , a loop diuretic, inhibits the NKCC1 transporter and renders GABA inhibitory.
Anesthesiology  •  2010  |  View Paper
Recent data highlight the potential of bumetanide as a treatment for neonatal seizures and autism, as it facilitates the excitatory to inhibitory switch in gamma‐aminobutyric acid signalling.
The Journal of pharmacy and pharmacology  •  2015  |  View Paper
Inhibition of NKCC1 with bumetanide reversed the paclitaxel effect on GABA-mediated hyperpolarization and GABA reversal potentials.
The Journal of Biological Chemistry  •  2014  |  View Paper
This EGABA shift was associated with increased expression of Na+–K+–2Cl− cotransporter 1 (NKCC1) in MNCs and was blocked by the NKCC inhibitor bumetanide as well as by decreasing NKCC activity through a reduction of extracellular sodium.
The Journal of Neuroscience  •  2011  |  View Paper
Bumetanide partially reduced DF(GABA) and therefore the excitatory action of GABA in epileptic neurons.
Journal of neurophysiology  •  2009  |  View Paper
Show More